Kyle Kline Files Form 3 Disclosing 51,591 GMED Option Shares

Rhea-AI Filing Summary

Kyle Kline, identified as Senior Vice President, Chief Financial Officer, filed an initial Form 3 reporting derivative holdings in Globus Medical, Inc. (GMED) related to stock options. The report, for an event dated 07/18/2025, lists seven option grants exercisable on dates from 01/25/2031 through 01/30/2035 covering a total of 51,591 underlying shares of Class A common stock. Strike prices on the grants range from $51.87 to $93.12, and each grant is reported as held directly. No non-derivative (direct) shares of common stock are reported on Table I. The filing is signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Transparency: The filing clearly discloses option grants totaling 51,591 underlying Class A shares with specific exercise prices and exercisable dates.
• Alignment: Multiple option grants across years indicate continued executive equity-based compensation that can align management incentives with shareholder value.

Negative

• No direct common stock reported: Table I shows no non-derivative holdings of Class A common stock by the reporting person.

Insights

Corporate Governance Expert

TL;DR: Routine initial ownership disclosure by a senior officer showing option awards; no unusual governance concerns evident.

The Form 3 formally notifies investors that the CFO holds multiple option grants totaling 51,591 underlying Class A shares with staggered exercisable dates through 2035. All positions are reported as direct, and there are no reported direct holdings of common stock in Table I. As an initial ownership statement, this is a standard Section 16 filing that increases transparency about executive compensation and potential future share issuance if options are exercised.

Executive Compensation Analyst

TL;DR: The filing documents routine equity compensation package components for a senior executive, offering alignment but no immediate cash impact.

The disclosed instruments are exclusively stock options with exercise prices between $51.87 and $93.12 and vesting schedules described in the explanations. The mix and timing of grants (2021–2025 grant dates) indicate ongoing equity-based pay practices. Because these are options (derivatives) rather than vested shares, they represent potential future dilution rather than current voting ownership.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kline Kyle

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/18/2025

3. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	(1)	01/25/2031	Class A Common Stock	5,000	$64.44	D
Stock Option (Right to Buy Class A Common Stock)	(2)	08/09/2031	Class A Common Stock	5,000	$80.17	D
Stock Option (Right to Buy Class A Common Stock)	(3)	01/27/2032	Class A Common Stock	5,000	$63.68	D
Stock Option (Right to Buy Class A Common Stock)	(4)	03/24/2033	Class A Common Stock	5,000	$53.14	D
Stock Option (Right to Buy Class A Common Stock)	(5)	02/27/2034	Class A Common Stock	15,000	$56.43	D
Stock Option (Right to Buy Class A Common Stock)	(6)	03/14/2034	Class A Common Stock	7,500	$51.87	D
Stock Option (Right to Buy Class A Common Stock)	(7)	01/30/2035	Class A Common Stock	9,091	$93.12	D

Explanation of Responses:

1. These options were granted on January 25, 2021, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2022, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

2. These options were granted on August 9, 2021, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on July 12, 2022, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

3. These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

4. These options were granted on March 24, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

5. These options were granted on February 27, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

6. These options were granted on March 14, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

7. These options were granted on January 30, 2025, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2026, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

	/s/ Kelly G. Huller, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for GMED?

The Form 3 was filed by Kyle Kline, identified as Senior Vice President and Chief Financial Officer of Globus Medical, Inc.

What securities are reported on this Form 3 for GMED?

The filing reports only stock options (derivative securities) covering 51,591 underlying shares of Class A common stock with various exercise prices and exercisable dates.

Are the reported options held directly or indirectly?

All option holdings on the Form 3 are reported as Direct (D) beneficial ownership.

What is the date of the event requiring the Form 3 filing?

The date of the event requiring the statement is 07/18/2025.

Does the Form 3 show any actual shares of common stock owned by the reporting person?

No. Table I contains no non-derivative (direct) shares; only derivative option grants are listed.